GlobeNewswire: Corium International, Inc. Contains the last 10 of 95 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T12:26:12ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/01/27/1975425/0/en/Corium-Inc-Announces-FDA-Filing-Acceptance-of-New-Drug-Application-for-ADLARITY-donepezil-transdermal-system-for-the-Treatment-of-Alzheimer-s-Disease.html?f=22&fvtc=4&fvtv=21550Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for ADLARITY® (donepezil transdermal system) for the Treatment of Alzheimer’s Disease2020-01-27T13:30:00Z<![CDATA[MENLO PARK, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Corium, Inc., a commercial-stage biopharmaceutical company leading the development of novel transdermal healthcare products that are intended to provide alternative treatment options for patients and their families, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for ADLARITY (donepezil transdermal system), its lead investigational agent for the treatment of dementia of the Alzheimer’s type in patients with mild, moderate, and severe Alzheimer’s disease. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of July 30th, 2020.]]>https://www.globenewswire.com/news-release/2019/04/02/1795773/0/en/Corium-Appoints-Perry-Sternberg-as-Chief-Executive-Officer.html?f=22&fvtc=4&fvtv=21550Corium Appoints Perry Sternberg as Chief Executive Officer2019-04-02T20:30:00Z<![CDATA[Former Shire Executive Brings Strong Track Record in Commercializing CNS Products Former Shire Executive Brings Strong Track Record in Commercializing CNS Products]]>https://www.globenewswire.com/news-release/2018/12/17/1668038/0/en/Corium-Announces-Offer-to-Purchase-for-Cash-Any-and-All-of-the-120-000-000-Aggregate-Outstanding-Principal-Amount-of-5-00-Convertible-Senior-Notes-due-2025.html?f=22&fvtc=4&fvtv=21550Corium Announces Offer to Purchase for Cash Any and All of the $120,000,000 Aggregate Outstanding Principal Amount of 5.00% Convertible Senior Notes due 20252018-12-17T14:30:00Z<![CDATA[MENLO PARK, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc., a Delaware corporation (“Corium”, the “Issuer”, “we”, “us” or “our”), today announced that, as a result of its acquisition by Gurnet Point Capital on November 27, 2018, it has commenced an offer to purchase any and all of its outstanding 5.00% Convertible Senior Notes due 2025, CUSIP No. 21887LAA5 (the “Notes”), issued and outstanding under the Indenture, dated as of March 5, 2018, as amended by the First Supplemental Indenture, dated as of November 27, 2018, as may be further amended or supplemented from time to time, (the “Indenture”), between the Issuer and U.S. Bank National Association, as trustee (the “Trustee”) for cash, upon the terms and conditions set forth in the Fundamental Change Notice and Offer to Purchase and in the accompanying Letter of Transmittal, at the Fundamental Change Purchase Price (as defined below) (the “Fundamental Change Repurchase”).]]>https://www.globenewswire.com/news-release/2018/10/11/1620284/0/en/Corium-Announces-Agreement-for-Gurnet-Point-Capital-to-Purchase-All-Outstanding-Shares.html?f=22&fvtc=4&fvtv=21550Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares2018-10-11T20:03:00Z<![CDATA[Total Transaction Valued in Excess of $500 Million, Representing a 50% Premium]]>https://www.globenewswire.com/news-release/2018/09/24/1574840/0/en/Corium-to-Present-at-the-2018-Cantor-Fitzgerald-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=21550Corium to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference2018-09-24T11:30:00Z<![CDATA[MENLO PARK, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, October 1, 2018 at 2:20 PM EDT.]]>https://www.globenewswire.com/news-release/2018/08/29/1558161/0/en/Corium-to-Present-at-the-H-C-Wainwright-20th-Annual-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=21550Corium to Present at the H. C. Wainwright 20th Annual Global Investment Conference2018-08-29T11:30:00Z<![CDATA[MENLO PARK, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 9:35 AM EDT.]]>https://www.globenewswire.com/news-release/2018/08/09/1549968/0/en/Corium-Reports-Third-Quarter-Fiscal-2018-Financial-Results-and-Corporate-Highlights.html?f=22&fvtc=4&fvtv=21550Corium Reports Third Quarter Fiscal 2018 Financial Results and Corporate Highlights2018-08-09T20:01:00Z<![CDATA[MENLO PARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third fiscal quarter and the nine months ended June 30, 2018 and reported on recent corporate developments. Corium's fiscal year ends on September 30.]]>https://www.globenewswire.com/news-release/2018/08/02/1546179/0/en/Corium-to-Report-Third-Quarter-Fiscal-2018-Financial-Results-on-Thursday-August-9-2018.html?f=22&fvtc=4&fvtv=21550Corium to Report Third Quarter Fiscal 2018 Financial Results on Thursday, August 9, 20182018-08-02T11:30:00Z<![CDATA[MENLO PARK, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ: CORI) today announced that it will report financial results for the third quarter ended June 30, 2018 on Thursday, August 9, 2018 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and report on recent progress.]]>https://www.globenewswire.com/news-release/2018/07/25/1542016/0/en/Corium-Presents-Additional-Positive-Clinical-Results-at-Alzheimer-s-Association-International-Conference-2018.html?f=22&fvtc=4&fvtv=21550Corium Presents Additional Positive Clinical Results at Alzheimer's Association International Conference® 20182018-07-25T14:30:00Z<![CDATA[Pharmacodynamic Results Further Support Therapeutic Equivalence of Corplex™ Donepezil to Aricept® Pharmacodynamic Results Further Support Therapeutic Equivalence of Corplex™ Donepezil to Aricept®]]>https://www.globenewswire.com/news-release/2018/07/11/1535843/0/en/Corium-Announces-Issuance-of-Additional-U-S-Patent-Covering-Corplex-Donepezil-Transdermal-System-for-Alzheimer-s-Disease.html?f=22&fvtc=4&fvtv=21550Corium Announces Issuance of Additional U.S. Patent Covering Corplex™ Donepezil Transdermal System for Alzheimer’s Disease2018-07-11T11:30:00Z<![CDATA[Second Orange Book Listable Patent Provides Expanded Coverage to 2037 Second Orange Book Listable Patent Provides Expanded Coverage to 2037]]>